India’s Banned Drug Dilemma Why Irrational FDCs Still Sell

#PharmaceuticalAccountability #BannedDrugsIndia #FDCBan #PatientRights #Berrybeat On 19 June 2026, India banned 16 more fixed-dose combination drugs. That sounds decisive. It should feel like progress. Yet the more uncomfortable truth is that India is still cleaning up a mess that regulators officially recognised a decade ago.

Fixed-dose combinations, or FDCs, are medicines that combine two or more active pharmaceutical ingredients in one pill, syrup, injection, or formulation. Some are useful. A properly tested combination can improve adherence, simplify treatment, and help patients take the right medicines at the right time.

The problem is irrational FDCs. These are combinations with no clear therapeutic justification, weak evidence, questionable dosing logic, or a risk profile that does not make sense. They can expose patients to unnecessary drugs, increase side effects, confuse diagnosis, and, in the case of antibiotics, worsen antimicrobial resistance.

India’s latest ban is not an isolated event. It is part of a long public health reckoning that began sharply in March 2016, when the government identified and banned 344 irrational FDCs. The pharmaceutical industry challenged that action in multiple High Courts. Companies including Pfizer, Abbott, Glenmark, and Macleods secured interim stays. Many products continued selling while legal and regulatory questions dragged on.

By June 2026, the tally had grown through incremental action: 14 more FDCs in 2023, 156 more in August 2024, and 16 more now. Still, hundreds of irrational combinations remain available in the Indian market.

That is the scandal inside the paperwork. A ban makes headlines. A stay order keeps a product alive. A prescription pad makes it normal. A patient swallows the risk without ever being told the story.

The FDC debate begins where most Indians meet the health system, at the pharmacy counter.

The 2026 ban is only the latest chapter in a much older failure

The phrase “India FDC ban 2026 irrational drugs” captures a live policy moment, but the real story is older and more tangled. India did not suddenly discover irrational combinations in 2026. Regulators, clinicians, pharmacists, and drug safety experts have warned about them for years.

The fixed dose combination ban India 344 2016 episode was a turning point because it put a large number on the table. The government said 344 combinations had no rational basis. This was not a small technical correction. It was a public admission that the market had allowed drugs to circulate without enough proof that the combinations served patients.

A simplified timeline shows how slowly the system moved.

Year	What happened	Why it matters
2016	Government identified and banned 344 irrational FDCs	The scale of the problem became impossible to ignore
2016 onward	Pharmaceutical companies challenged the ban in courts	Legal stays allowed several products to remain on shelves
2023	14 more FDCs were banned	The clean-up continued, but in fragments
August 2024	156 more FDCs were banned	The list widened again, showing the problem had not been solved
19 June 2026	16 more FDCs were banned	The regulatory reckoning entered another round

The core issue is simple to understand. A medicine is not safer because it is familiar. A combination is not rational because it sells well. A prescription is not proof of evidence.

FDCs can make sense when the combination has been properly studied. For example, some treatments for tuberculosis, HIV, diabetes, and hypertension use combinations for clear medical reasons. They can reduce pill burden and improve adherence, especially in long-term care.

Irrational FDCs are a different creature. They can combine drugs that do not need to be taken together. They can contain ingredients with mismatched dosing schedules. They can mix an antibiotic with another medicine in ways that encourage misuse. They can turn a simple fever, cough, or pain consultation into exposure to two, three, or more active ingredients that the patient did not need.

This matters in India because medicines are often treated as everyday consumer goods. A busy pharmacy may sell a familiar brand because the patient used it earlier. A patient may ask for “strong” medicine. A doctor under heavy outpatient pressure may prescribe a combination that appears convenient. A medical representative may keep the brand visible through clinic visits and samples.

Once a drug becomes routine, the question “Does this combination need to exist?” gets pushed aside.

That is how irrational medicine becomes ordinary medicine.

A ban elsewhere rarely reaches the Indian patient

The Indian patient rarely knows whether a prescribed drug has been restricted or banned elsewhere. The doctor may know, but may not have the time or habit of checking international safety histories during a rushed consultation. The pharmacist may focus on availability and substitution. The pharmaceutical representative often knows exactly where the product stands, which brands compete with it, and how to keep it in circulation.

That knowledge gap is not accidental. It is structural.

Take nimesulide. The phrase Nimesulide banned India US EU has become a shorthand for a larger discomfort. Nimesulide, a non-steroidal anti-inflammatory drug, has faced bans or severe restrictions in several high-income jurisdictions for systemic use because of liver toxicity concerns. In India, it was widely prescribed for fever and pain for decades, including in settings where safer and better-known alternatives existed.

Analgin, also known as metamizole, raises similar questions. It is banned in the United States because of safety concerns, yet remains available in India. Different countries can make different regulatory choices, and a foreign ban does not automatically settle every scientific question for India. But it should trigger a serious public conversation. It should lead to visible labelling, strong pharmacovigilance, and clear prescribing guidance.

Instead, Indian patients often get silence.

The problem becomes even more urgent with antibiotic FDCs. Some antibiotic combinations rejected by Western regulators continue to be marketed in India. Public health experts worry because antibiotic misuse does not harm only one patient. It feeds antimicrobial resistance, which makes infections harder to treat across communities.

A fever treated with an unnecessary antibiotic is not a small private event. It is part of a national resistance story.

The deeper challenge was captured by a pharmaceutical expert quoted in The Print:

“The absence of evidence of harm is not evidence of absence of harm. We simply did not have a system of pharmacovigilance 30 years ago and could not show how the drugs do harm.”

That quote should be printed on the wall of every drug regulator and every medical college pharmacology department.

For years, India’s drug market grew faster than its safety surveillance capacity. If a medicine caused harm that was subtle, delayed, under-reported, or misattributed to illness, the system often failed to capture it. A patient with liver injury may not connect it to a painkiller. A family may not report an adverse drug reaction. A doctor may not file a formal report. A small clinic may lack time, systems, or incentives to document harm.

No report, no signal. No signal, no action. No action, continued sales.

This is why “absence of harm” can become a dangerous illusion.

Many patients never learn whether a familiar medicine has faced restrictions abroad.

The market rewards combinations before evidence catches up

India’s FDC problem is not only a regulatory failure. It is also a market design failure.

A single active ingredient can quickly become a crowded category. Many companies sell versions of the same molecule. Prices face pressure. Differentiation becomes harder. An FDC offers a way to create a new brand identity, a new claim, and a new reason for a doctor to remember the product.

This is not always sinister. Some combinations are clinically sound. But the commercial incentive is obvious. Combine ingredients, create a brand, position it as broader, stronger, faster, or more convenient, and push it through prescription networks.

That is why fixed-dose combinations are so attractive in a country where branded generics dominate. A patient may not know the molecule. The patient knows the strip colour, the brand name, the chemist’s suggestion, or the doctor’s handwriting. Once the brand becomes familiar, it develops its own life.

Irrational FDCs exploit three weak points.

The first weak point is information asymmetry.

The manufacturer knows the formulation. The representative knows the sales pitch. The doctor may know the ingredients but may not know the full regulatory history. The patient usually knows least of all.

A combination pill can look simple. One tablet. One syrup. One sachet. Yet it may contain multiple active ingredients, each with its own risks, interactions, and dosing considerations. The patient sees convenience. The body receives complexity.

The second weak point is weak post-market surveillance.

India has improved pharmacovigilance over time, but under-reporting remains a serious barrier. Adverse drug reactions are hard to identify without systematic reporting. They are even harder to connect to irrational combinations, especially when patients take several medicines at once.

For drug safety, the market cannot be the laboratory. Patients should not become the evidence base after approval. When a combination lacks therapeutic justification, the burden should fall on the manufacturer to prove value, not on the injured patient to prove harm.

The third weak point is prescription culture.

Many Indians expect medicine at the end of a consultation. In fever, cough, body ache, acidity, or diarrhoea, a prescription with multiple products can feel like better care. Doctors face pressure too. They work under heavy patient loads, often with limited time to explain why rest, fluids, monitoring, or a single medicine may be enough.

This culture rewards visible treatment. It punishes restraint.

The strongest clinicians know that good medicine often means saying no: no unnecessary antibiotic, no unnecessary steroid, no irrational combination, no extra pill just to satisfy expectation. But ethical restraint becomes harder when the market keeps offering convenient shortcuts.

This is where CM Gulhati, editor of the Monthly Index of Medical Specialities, cut through the fog during the 2016 controversy:

“90% are irrational and we have no business letting our people consume all sorts of funny combinations that are no longer in use globally.”

The quote is blunt. It is also morally clear. A country should not become a dumping ground for combinations that would struggle to survive scrutiny elsewhere.

The doctor incentive problem is real, and voluntary codes are not enough

No serious discussion of irrational FDCs can avoid the relationship between pharmaceutical companies and prescribers.

India has rules on paper. The Medical Council of India’s ethics code prohibits doctors from accepting gifts and other inducements from pharmaceutical companies. The Uniform Code of Pharmaceutical Marketing Practices has been discussed for mandatory implementation since 2012. Yet it has remained voluntary.

That gap matters.

A voluntary code can be useful when companies want to act responsibly. It is weak when aggressive marketing rewards those who push boundaries. If one company refuses gifts, sponsored hospitality, or indirect inducements while another uses them, the ethical company may feel commercially punished. Voluntary compliance can become a race where the most restrained actor loses.

This is why India pharma doctor incentives marketing is not a side issue. It sits close to the heart of the irrational FDC problem.

The influence does not always look dramatic. It may not be a suitcase of cash or a luxury trip. It can be a steady drip of reminders, samples, sponsored events, conference support, clinic materials, favourable brand recall, and social familiarity. In a crowded prescription market, repeated visibility works.

A medical representative who visits on Tuesday may know:

• which combinations face regulatory criticism

• which brands survived legal challenges

• which doctors prescribe competing products

• which formulations are moving fastest

• which products are difficult to defend scientifically but easy to sell commercially

  
  

The patient almost never has this information.

That imbalance should disturb us. The person taking the risk is the least informed person in the chain.

Doctors deserve a fair reading here. Many prescribe ethically under exhausting conditions. Many reject inducements. Many keep learning, update their practice, and protect patients from unnecessary drugs. Pharmacists too often catch dangerous duplications and counsel patients with care.

But systems should not depend on individual virtue alone. Public health needs enforceable norms. If marketing practices influence prescriptions, then marketing practices must face real scrutiny.

A mandatory UCPMP with penalties, disclosure requirements, audit trails, and public reporting would not solve everything. It would make the invisible visible. It would also send a message that prescription decisions belong to evidence, not sales pressure.

Prescription culture and pharmacy access shape how irrational medicines remain normal.

Courts, regulators, and companies must stop passing the patient around

The 2016 ban exposed a difficult triangle: regulators, courts, and industry.

Regulators moved against hundreds of FDCs. Companies challenged the bans. Courts granted interim relief in several cases. From a legal standpoint, companies have the right to challenge government action. Due process matters. Regulators must follow proper procedure, use expert committees, give reasons, and respect the law.

But public health suffers when legal delay becomes market permission.

If a product lacks therapeutic justification, the default should not be years of continued normal sales. Interim stays may protect a company from unfair regulatory action, but they can also expose patients to questionable products while the system debates procedure. The law must find a way to protect both fairness and safety.

A better framework would ask sharper questions.

Has the manufacturer submitted strong evidence that the combination works better than its separate ingredients?

Does the dosing ratio make clinical sense across patient groups?

Does the combination increase exposure to unnecessary antibiotics, painkillers, antihistamines, steroids, or other drugs?

Is the product approved by the central regulator, or did it enter through older state-level pathways that created inconsistency?

Is there a clear adverse event reporting record?

Have other regulators raised safety concerns?

These are not anti-industry questions. They are pro-patient questions. A credible pharmaceutical industry should welcome them because irrational products damage trust in the whole sector.

India has world-class pharmaceutical manufacturing capacity. It supplies medicines across the globe. It produces affordable generics that save lives. That achievement is real and worth defending. The defence cannot be to tolerate irrational combinations at home. The defence must be higher standards.

The CDSCO banned drugs sold India problem, as many patients understand it, is less about one agency and more about scattered accountability. The Centre may ban. A company may litigate. A state regulator may have issued an approval in the past. A chemist may still have stock. A doctor may still remember the brand. A patient may assume availability means safety.

Availability is not a safety certificate.

This is the sentence that should define drug regulation in India for the next decade.

What a safer Indian medicines market should look like

The solution is not panic. It is not rejecting every FDC. It is not treating every doctor as compromised or every pharmaceutical company as predatory. The solution is a cleaner, stricter, more transparent medicines market.

A rational FDC policy should rest on five changes.

Create a public, searchable FDC registry.

Every approved FDC should be listed with ingredients, approved indications, approval pathway, safety warnings, and regulatory status. Patients, doctors, pharmacists, journalists, and researchers should not have to chase scattered notifications.

If a drug is banned, stayed, under review, or restricted, that status should be easy to find in plain language.

Make evidence mandatory before market access.

Manufacturers should prove that a combination offers a real clinical advantage. Convenience alone should not be enough. A brand should not enter the market simply because its ingredients are individually approved.

The combination is a new therapeutic claim. It deserves evidence.

Strengthen pharmacovigilance where patients actually receive care.

Adverse drug reaction reporting must become easier in hospitals, clinics, pharmacies, and digital health platforms. Reporting should take minutes, not paperwork marathons. Medical colleges and district hospitals can become stronger signal centres.

Patients should also have a simple way to report suspected reactions, with safeguards against noise and misuse.

Make pharma marketing rules mandatory.

A voluntary code cannot carry the weight of public trust. India needs binding rules on gifts, sponsorships, samples, hospitality, speaker fees, and indirect benefits. Violations should carry consequences for companies, not only doctors.

Transparency will not eliminate influence, but it will reduce secrecy.

Teach prescription restraint as a mark of excellence.

Medical education should celebrate rational prescribing. Pharmacology should not feel like a forgotten exam subject. It should sit at the centre of clinical judgement.

A good prescription is not the longest prescription. A strong doctor is not the one who writes the newest brand. A responsible pharmacist is not the one who substitutes without thought. Rational medicine is a professional skill and a public duty.

A safer medicines market also needs clearer information inside Indian homes.

The questions patients can ask without becoming their own doctors

Patients should not have to become pharmacologists to stay safe. The burden belongs to regulators, manufacturers, doctors, and pharmacists. Still, a few questions can shift the consultation in a healthier direction.

When prescribed a combination medicine, a patient can ask:

• What are the active ingredients in this medicine?

• Why do I need this combination instead of a single medicine?

• Is there an antibiotic, steroid, or strong painkiller in it?

• How many days should I take it?

• What side effects should make me stop and call you?

• Is this safe with my liver, kidney, pregnancy status, age, or other medicines?

• Is there a simpler alternative?

  
  

These questions are not confrontational. They are part of informed care.

For doctors, the ethical clarity is just as direct. If a combination has no clear rationale, do not prescribe it. If a brand survives mainly because of marketing, avoid it. If a patient expects “strong medicine”, explain why unnecessary ingredients can cause harm. If uncertain, check an updated formulary, standard treatment guideline, or reliable drug reference.

For pharmacists, the role is powerful. A pharmacist can spot ingredient duplication, warn against unsafe self-medication, and encourage patients to return to the prescriber when a combination seems inappropriate. In many Indian neighbourhoods, the pharmacist is the most accessible health professional. That access can either normalise irrational drugs or challenge them.

For industry, the path is obvious. Build trust by withdrawing weak products, publishing evidence, respecting stricter marketing norms, and treating Indian patients with the same seriousness expected in export markets.

The old excuse that “there is demand” is not enough. Demand can be manufactured. Habit can be cultivated. Brand recall can be purchased. Public health cannot be left to those forces.

The real dilemma is not whether India can ban irrational drugs

India can ban irrational drugs. It has done so repeatedly. The real dilemma is whether India can build a system where irrational combinations do not flourish for years before the ban arrives.

That means faster expert review, cleaner approval pathways, stronger post-market surveillance, binding marketing rules, and public access to medicine safety information. It also means changing the culture of prescription from more to better.

The 19 June 2026 ban of 16 FDCs should be welcomed, but not mistaken for closure. It is another correction in a market that still needs a deeper reset.

The Indian patient deserves to know more than the colour of a strip and the timing of a dose. The patient deserves to know that the medicine has a reason to exist, that its risks are tracked, that its marketing is clean, and that its continued sale reflects evidence rather than inertia.

A country that can manufacture medicines for the world can certainly demand rational medicines for its own people.

This article is for general information only and is not medical advice. Do not stop or change prescribed medicines without consulting a qualified healthcare professional.